Mizuho Reduces PT on Haemonetics Corporation (HAE) Following Fiscal Q1 2025 Results

Haemonetics Corporation (NYSE:HAE) is one of the 13 Oversold Value Stocks to Invest in Now.

On August 14, 2025, Mizuho reduced its price target on Haemonetics Corporation (NYSE:HAE) from $90 to $70, maintaining an ‘Outperform’ rating. This price revision follows the company’s fiscal Q1 results.

For Q1, Haemonetics Corporation (NYSE:HAE) reported a $20 million revenue beat, alongside earnings that surpassed estimates by $0.09 per share. The company’s robust performance was driven by strong Plasma and Blood Center results. However, its share price declined 26% amid concerns over slowing growth in the VASCADE MVP product line. The VASCADE MVP segment decelerated to 6% from 28% last quarter. Furthermore, Mizuho highlighted the company’s leadership strategy shifts and competitive pressures, citing them as key concerns. Looking ahead, the analyst expects recovery to take at least six months.

Haemonetics Corporation (NYSE:HAE), a global medical technology firm, delivers plasma collection systems, donor management software, and advanced hospital solutions, including electrophysiology, trauma, surgery, and critical care. It is one of the oversold stocks.

While we acknowledge the potential of FICO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 13 Hot Oil Stocks to Buy Now.

Disclosure: None.